The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person

Sponsor
Martine Puts (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05509751
Collaborator
University Health Network, Toronto (Other), Sunnybrook Health Sciences Centre (Other)
60
2
2
39
30
0.8

Study Details

Study Description

Brief Summary

Phase 2 randomized controlled study using a waitlist control group.

Study Duration 2.5 years

Study Agent/ Intervention/ Procedure Comprehensive Geriatric Assessment and Management (GAM) combined with online chair-based exercise (CBE) and health education for 12 weeks.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: GAM, exercise, health education
N/A

Detailed Description

The purpose of this randomized clinical trial is to compare the standard of care alone to using a detailed health assessment for older adults followed by a 12 week program of online physical activity and health education (also called the intervention) plus the standard of care. The addition of the detailed health assessment for older adults followed by a 12 week program of online physical activity and health education to the standard of care could benefit older adults with cancer in terms of improving their physical activity, muscle strength, quality of life, and fatigue.

The intervention group will receive a detailed health assessment for older adults followed by a 12- week program of physical activity and health education. During the assessment they will be asked to provide information on current health, mood, weight loss, vision and hearing, memory, fatigue, pain, and a review of medications. Additionally, they will be asked to undergo a few tests that assess walking, grip strength, and balance and complete questionnaires that evaluate quality of life, fatigue, anxiety, depression, and physical function.

Two weekly sessions of group-based exercise (20-40) minutes are conducted via Zoom by a qualified exercise professional. These sessions include aerobic exercise for 20 minutes; resistance training, for 10 minutes; balance training 8 minutes, and flexibility training for 7 minutes. They will receive a weekly check-in to discuss the exercises and progress with the QEP who will adjust the exercises based on tolerance. During the first session of each of the 12- weeks, a video about a health topic by an expert will be shown on Zoom so that they can think about it after the class and prepare questions for the discussion with the expert.

Their support person are invited to participate in this study. We assume that involving support persons in this study, including exercising together, can improve the health and quality of life of the patient and and their support person. If they or their support person do not have a tablet/laptop to join the class, this will be provided along with training on how to use them.

The control group will receive usual care and the option to receive the intervention after 12 weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
The study statistician will be blinded to group allocation
Primary Purpose:
Supportive Care
Official Title:
Supporting Older Adults With Cancer and Their Support Person Through Geriatric Assessment and Remote Exercise and Education: the SOAR Study
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Intervention group

geriatric assessment (GAM) and remote exercise and education prior to and during curative/adjuvant or first/second line palliative chemotherapy /immunotherapy or targeted therapy

Behavioral: GAM, exercise, health education
geriatric assessment, exercise and health education
Other Names:
  • Comprehensive Geriatric Assessment and Management (GAM) combined with online chair-based exercise (CBE) and health education for 12 weeks.
  • No Intervention: Waitlist control group

    Wait list, receiving standard of care and option to receive intervention after treatment.

    Outcome Measures

    Primary Outcome Measures

    1. Feasability of the study [12 weeks]

      What is the feasibility of implementation of the study? Feasibility will be measured by recruitment rate which will be the proportion of eligible patients and support persons who agree to enroll in the study, collected from our recruitment log) and measured in percentage with range 0-100. Feasibility of retention will be measured proportion of participants who complete the study data collection, collected from our study log), range 0-100. Feasibility of data outcome collection will be the percentage of patients who have complete data collection (collected from our study log), range 0-100. Feasibility of the study will be defined as recruitment of >60% of all eligible older adults; retention of >80% of the dyads; and 3) capture of outcome data of 80% or more.

    2. Acceptability of the intervention and the study [12 weeks]

      What is the acceptability of the intervention and study? Acceptability will be measured by 1) adherence to the intervention and 2) satisfaction. Adherence to the intervention= 1) adherence to the geriatric assessment recommendations (collected through chart review) and expressed as percentage of recommendations received and implemented by the patient, range 0-100. 2) Adherence to online classes will be measured through the number of sessions missed as documented in the intervention log. A 5-item Likert scale satisfaction with the study scale ranging from very satisfied to very unsatisfied and satisfied and very Satisfied= satisified. Acceptability will be defined as 1) adherence to the intervention of >85% of participants adhering to at least 80% of the classes and recommendations; 2) satisfaction by 80% of participants.

    Secondary Outcome Measures

    1. Effect intervention on Physical function [12 weeks]

      What are the preliminary estimate of the intervention on physical function? This will be measured with the Short Physical Performance Battery (SPPB). The Short Physical Performance Battery is a test battery comprising of a four-meter gait speed test, a balance test, and 5 timed chair stand tests. The total score ranges between 0-12, and a change of one point is considered the minimal clinically important difference (MCID).

    2. Effect intervention on Grip strength [12 weeks]

      What are the preliminary estimates of the intervention on grip strength? Grip strength in kilos will be measured with a handheld dynamometer three times in the dominant hand (range 0-80 kg). The maximum score will be used, and the minimal clinically important difference (MCID) is 5 kg.

    3. Effect intervention on Life space Mobility [12 weeks]

      What are the preliminary estimates of the intervention on Life Space Mobility? Life Space Mobility (LSM) will be measured with the University of Alabama Birmingham Study of Aging Life Space Assessment. The Life Space Mobility total score ranges from 0 (bed-bound) to 120 (daily independent out-of-town mobility). The minimal clinically important difference (MCID)is five points.

    4. Effect intervention on Physical Activity [12 weeks]

      What are the preliminary estimates of the intervention on Physical Activity? Physical activity will be measured with the Godin Leisure time Exercise questionnaire. It asks how many times in the past seven days the participant has done vigorous, moderate, and light exercise for at least 15 min each time, and how much time the participant spent on the exercise, to calculate the total score. A score of 24+ indicates Active, 14 - 23 indicates Moderately Active, and <14 indicates inactive/sedentary

    5. Effect intervention on number of self-reported Falls [12 weeks]

      What are the preliminary estimates of the intervention on the number of self-reported falls? Self-reported falls will be assessed weekly by a phone call by the RA as well as circumstances of the fall and will be scored as the total number of falls (ranging from 0- 200).

    6. Effect of the intervention on Fatigue [12 weeks]

      What are the preliminary estimates of the intervention on fatigue? This will be measured with the Pittsburgh Fatigability questionnaire (PFS). The Pittsburgh Fatigability questionnaire measures both physical and mental fatigability. Participants rate their tiredness/exhaustion from 0 ("no fatigue") to 5 ("extreme fatigue") for how they expected or imagined they would feel after completing activities ranging in type and intensity (10 items). Continuous scores for each dimension can range from 0 to 50, with higher scores indicating higher fatigability and scores >25 will be used to indicate severe fatigability.

    7. Effect of the intervention on Quality of life [12 weeks]

      What are the preliminary estimates of intervention on quality of life? This will be measured with the 12-item Short Form Survey (SF-12) . The 12 items are summarized in a physical subscale ranging from 0-100 and a mental health subscale ranging from 0-100.

    8. Effect of the intervention on treatment toxicity [12 weeks]

      What are the effect of the intervention on Treatment toxicity ? This will be abstracted from the medical charts and treatment toxicity will be graded using the Common Terminology Criteria for Adverse Events version 5.0. Each toxicity is graded from 0-5. The number of toxicities grade 3-5 will be summed.

    9. Effect of the intervention on unplanned healthcare utilization [12 weeks]

      What are the effect of the intervention on unplanned Emergency Department (ED) visits and/or hospitalization? This will be abstracted from the medical charts and summarized as the number of unplanned emergency department visits and number of unplanned hospitalizations. Both could range from 0-100.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    70 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Aged 70+ years.

    2. Score >3 (indicating frailty) using the Vulnerable Elders Survey-13 (VES-13);

    3. Diagnosed with lung or gastrointestinal (GI) cancer who are referred for first or second-line chemotherapy or immunotherapy and have not received > 4 weeks of systemic treatment.

    4. Have a physician estimated life expectancy of >6 months.

    5. Be physically inactive (no more than 90 min moderate to vigorous activity per week as per GLTEQ and do not currently meet the recommended physical activity volume of 90 min of aerobic exercise/week).

    6. Able to speak and understand English.

    7. Able to give informed consent.

    8. Are considered safe to participate in the weekly classes as per their treating oncologist.

    Eligible support persons are:
    1. Identified by the older adult as their support person.

    2. Aged 18 years and over.

    3. Able to speak and understand English.

    4. Able to give informed consent.

    Exclusion Criteria:
    1. Severe neuropsychiatric abnormalities (e.g., moderate-severe dementia) per the treating physician; and

    2. Clinic visit with a geriatrician in the previous 12 months (they have already received part of the intervention).

    Exclusion criteria support person:

    Not able to give informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Princess Margaret Cancer Centre Toronto Ontario Canada M5T 2M9
    2 Sunybrook Health Sciences Centre, Odette Cancer Centre Toronto Ontario Canada

    Sponsors and Collaborators

    • Martine Puts
    • University Health Network, Toronto
    • Sunnybrook Health Sciences Centre

    Investigators

    • Principal Investigator: Martine Puts, RN PhD, University of Toronto

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Martine Puts, Associate professor, University of Toronto
    ClinicalTrials.gov Identifier:
    NCT05509751
    Other Study ID Numbers:
    • CTO#4087
    First Posted:
    Aug 22, 2022
    Last Update Posted:
    Aug 22, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Martine Puts, Associate professor, University of Toronto
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 22, 2022